Tesamorelin mechanism, half-life, and the published corpus — without the bro-science. A founder-operator reading of the stabilized GHRH analog with the cleanest Tier-1 record.
Tesamorelin is the GH-axis compound with the cleanest published outcome data. It is the only molecule on this page set with an FDA-approved indication that has not been discontinued. That regulatory record reshapes how everything downstream of it should be read. The off-label founder-operator use is built on top of a registration package most of the other compounds on this page do not have.
This page is the working reference. Mechanism, half-life, the corpus, the gaps. The regulatory record is stated as record, not endorsement.
Tesamorelin is a synthetic GHRH analog. The molecule is human GHRH(1-44) with a trans-3-hexenoyl modification at the N-terminus. The modification protects the position-2 cleavage site that DPP-IV uses to clear native GHRH, producing a meaningfully longer plasma residence than native GHRH or Sermorelin while retaining full GHRH-receptor activity.
The regulatory note belongs at the top. Tesamorelin holds an FDA-approved indication for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, marketed as Egrifta. This is regulatory record. It is not an endorsement of the molecule for any other use, not a recommendation for off-label administration, and not a clinical claim. The point of stating it is that Tesamorelin sits in a different evidence-and-regulatory tier from the research-only GHRH analogs that dominate the founder-operator stack discussions. The Phase 3 program that produced the approval is the largest set of randomized human outcomes data on any GHRH analog discussed across this page set.
Tesamorelin binds the GHRH receptor on pituitary somatotrophs and drives GH synthesis and pulsatile release through the same cAMP-mediated cascade as Sermorelin and CJC-1295. The downstream consequences — circulating GH, hepatic IGF-1, peripheral GH-receptor and IGF-1-receptor signaling — are the GHRH-axis pharmacology common to the class.
The trans-3-hexenoyl modification at the N-terminus is the structural feature that distinguishes Tesamorelin from Sermorelin. It blocks the DPP-IV cleavage site that clears native GRF(1-29)NH2 in minutes, producing the longer plasma half-life characterized below. It does not alter the receptor-binding face of the molecule. From the somatotroph's perspective, Tesamorelin is GHRH; from the protease's perspective, it is not GRF(1-29)NH2.
Falutz and colleagues at McGill ran the registration program that produced the FDA approval. The Falutz Phase 3 papers — beginning with the 2007 New England Journal of Medicine paper and continuing through the extension and follow-on publications — characterized GH and IGF-1 responses, body composition outcomes, glucose effects, and the visceral-adipose-tissue reduction that became the indication. This corpus is the deepest set of randomized human GHRH-analog data in print.
Two mechanism notes worth being explicit about. First: the visceral-adipose-tissue reduction observed in the registration program is the body composition signal that operators most often reference, but the trial population — HIV lipodystrophy — has a specific underlying physiology, and effects in that population do not generalize automatically to healthy adults. The published outcome data is what it is; the inference to off-label adult use is the inferential step. Second: like the rest of the GHRH-analog class, Tesamorelin acts upstream of the pituitary. It does not provide GH directly. Pituitary integrity is a precondition.
Tesamorelin has a reported plasma half-life of approximately 30 minutes after subcutaneous administration. This is shorter than CJC-1295 with DAC by orders of magnitude, longer than Sermorelin by a factor of roughly two, and roughly comparable to CJC-1295 without DAC.
The 30-minute plasma half-life produces a pulse-shaped exposure rather than a depot. Daily subcutaneous administration is the route in the registration program. The molecule is functionally short-acting at the timescale that matters for GH pulse architecture — administration produces a single GH pulse, not a multi-day elevation.
Route in published work is subcutaneous injection. The Egrifta product is provided as a lyophilized powder for reconstitution and subcutaneous administration. This is the route that the registration program ran on and the route the off-label adult-use literature observes.
The pulse-versus-depot argument that runs through the GHRH-analog discussion lands on Tesamorelin as a pulse molecule. The largest randomized human outcomes corpus in the class is on a pulse-administered GHRH analog. This is a fact about the evidence base that the discussion frequently glosses past.
Tesamorelin sits at Tier 1 in our framework for its labeled HIV-lipodystrophy indication. This is the strongest evidence position of any compound on this page set.
What the published Tier 1 work establishes (regulatory record — HIV lipodystrophy):
What the published work does not establish:
The off-label adult use the founder cohort runs is Tier 4 — extrapolated from the Tier 1 mechanism and outcome data, observed in compounding-pharmacy clinical reports and N=1, and not the same evidence type as the registration package.
This is the cleanest tier separation on the page set. The Tier 1 record is real. The Tier 4 inference is real. They are not the same thing, and the discourse frequently collapses them into one.
Tesamorelin community reports are smaller in volume than CJC-1295 and Ipamorelin reports — the molecule is more expensive at clinical-grade and is harder to source than the research-peptide GHRH analogs — but the reports are dense in detail.
Visceral-fat reports dominate the off-label adult-use discussion. Users in the multi-month window describe waist-circumference reductions and abdominal-composition changes consistent with the labeled-indication mechanism. The reports tend to track the trial-population pattern more closely than other GH-axis compounds' reports do, which is what one would expect from the closer match between the off-label use and the labeled mechanism.
Sleep-architecture reports are present and consistent with the GH-axis pattern across this page set.
Glucose reports are the meaningful place where Tesamorelin-specific community caution shows up. The labeled product carries a glucose-effect note in the registration package, and off-label users report watching fasting glucose and HbA1c during use more than they do on the other GHRH analogs.
PIP reports vary by source. Clinical-grade product is more uniform than research-market product, as one would expect.
We do not have a randomized outcome trial of Tesamorelin in healthy adults on body composition, recovery, or longevity-relevant endpoints. The HIV-lipodystrophy registration program is not that trial.
We do not have long-term safety data on Tesamorelin use in healthy adults over years. The labeled-indication safety record is informative but is observed in a different population over a defined window.
We do not have head-to-head comparative outcome data on Tesamorelin versus Sermorelin or versus CJC-1295 in healthy adults. The choice between them is being made on mechanism, half-life preference, supply-chain availability, and cost — not on outcome data.
We do not have a settled answer to whether the visceral-adipose-tissue effect characterized in the HIV-lipodystrophy population is mechanistically reproducible at meaningful magnitudes in healthy adult founders, or whether the population-specific physiology is doing more of the work than the molecule is. This is a real open question and one the off-label literature has not addressed at the evidence tier the labeled-indication literature represents.
Issue 1 of The Compound is the GH-axis primer for founder-operators. Tesamorelin anchors the Tier-1 end of that issue — it is the compound on the GH-axis page with the deepest randomized human outcomes corpus, regardless of population.
The active question for much of the founder cohort right now is lean-mass preservation under GLP-1 administration. GH-axis activation is one of the better-characterized mechanisms for protecting lean mass during caloric deficit, and Tesamorelin and Sermorelin are the GH-axis compounds with the cleanest regulatory records and the deepest mechanistic story behind them. The GLP-1 Muscle Preservation lead magnet on this page is the working reference for that question — what the corpus shows on lean mass under GLP-1 cuts, what the GH-axis adds, and where the literature thins.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound. The HIV lipodystrophy indication referenced above is regulatory record and is not an endorsement of the molecule for any other use.
FTC disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators.
[Subscribe — get the GLP-1 Muscle Preservation brief]
What survives Phase 3, what survives the field. The 39% question, decoded.
Download the PDF →